Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Random-effects meta-analyses show the upregulated NSUN2 and IGF-II expression in ovarian cancer versus normal tissues.
|
28829218 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
|
24727326 |
2014 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to validate IGF2 as a potential therapeutic target in drug resistant ovarian cancer and to determine the efficacy of targeting IGF2 in vivo.
|
24932685 |
2014 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.
|
24872956 |
2014 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results show that i) aPC induced the secretion of several cytokines in Ovcar-3 cells; ii) 61% of patients exhibited a concentration of plasma sEPCR well above the baseline (normal plasma level, 100 ± 28 ng/ml); iii) comparing immune cell phenotypes in patients having a normal level of sEPCR with those having a high level of sEPCR, it was found that sEPCR levels were correlated with high intensity of cells expressing CD45ra, CD3, CD8, CD25 and low intensity of cells expressing CD56 (NK cells), CD294 (TH2 cells), IL-2, IL-10, IL-17a (TH17 cells), IL-21 (TH21 cells) and CD29 markers (r ≥ 0.60); and iv) high levels of sEPCR correlate with high levels of plasma bioactive proteins such as insulin-like growth factor-2 (IGFII), IL-13rα, macrophage inflammatory protein (MIP1α) and matrix metalloproteinase-7 (MMP-7) that have already been proposed as biomarkers for ovarian cancer and particularly those with poor prognosis.
|
23877403 |
2013 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We determined whether rs4320932 is associated with IGF-II expression and patient survival in ovarian cancer, and explored whether the SNP variation affects DNA conformation both in the absence of and presence of carboplatin.
|
23677070 |
2013 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.
|
21422097 |
2011 |
Malignant neoplasm of ovary
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The study suggests that DNA methylation regulates IGF-II promoter-specific expression in ovarian cancer and the regulation may play a role in disease progression.
|
21109978 |
2011 |
Malignant neoplasm of ovary
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In summary, we found frequent combined aberrant methylation of the IGF2-H19 locus and LINE1 in the vast majority of OC, suggesting that these changes are important events in tumorigenesis.
|
19956846 |
2010 |
Malignant neoplasm of ovary
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
IGF-II promoter methylation and ovarian cancer prognosis.
|
17569086 |
2007 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated IGF2 expression is a frequent event in serous ovarian cancer and this occurs in the absence of IGF2 LOI.
|
16603642 |
2006 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of the current study is to further elucidate the role of the IGF-2 gene in ovarian cancer development and progression.
|
15661221 |
2005 |
Malignant neoplasm of ovary
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
LOI of IGF-II and H19 genes may be involved in the development of ovarian cancer.
|
10690526 |
2000 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that IGFII may be a potential target in treatment of ovarian cancer and antisense oligonucleotide to IGFII may serve as a therapeutic approach.
|
9669031 |
1998 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The data suggest that the increased IGF2 gene expression in ovarian cancer may be achieved by a mechanism other than loss of imprinting.
|
8644850 |
1996 |